PARAMETERS OF THE LIPID PROFILE IN DONORS WHO HAD SUFFERED FROM COVID-19 AND HAD VARIOUS TITERS OF ANTI-SARS-CoV-2 IgG IN BLOOD PLASMA
DOI 10.17721/1728.2748.2023.92.22-26
Keywords:
anti-SARS-CoV-2 IgG, total cholesterol, HDL, LDL, VLDL, TGAbstract
COVID-19, caused by SARS-CoV-2, is a systemic disorder of with possible pathological complications in human organism. One of the critical targets of SARS-CoV-2 is the metabolism of lipids and products, which may influence the changes in patients with illness. Currently, the mechanism of binding between SARS-CoV-2 and lipids, as well as the consequences of these processes, is unknown. In addition, the long post-COVID-19 period has been confirmed in the majority of people who have suffered from COVID-19; therefore, additional attention should be paid to studying the biochemical parameters of lipid metabolism after SARS-CoV-2 infection. Our work is aimed the studying of lipid profile including concentration of total cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides (TG) in donor groups who had suffered from COVID-19 and had different titers of anti-SARS-CoV-2 IgG in blood plasma. We selected donor groups with maximum and minimum changes of parameters among donor groups with titers of anti-SARS-CoV-2 IgG ≥ 10 Index (S/C), than we compared these groups to donor group with titer of anti-SARS-CoV-2 IgG 0 Index (S/C). We established that the donor group with titer of anti-SARS-CoV-2 95 ± 5 Index (S/C) was characterized by the maximum concentration of total cholesterol, LDL, VLDL, TG, while the donor group with titer of anti-SARS-CoV-2 IgG 75 ± 5 Index (S/C) was determined as the minimum concentration of total cholesterol, HDL, LDL. In addition, donor group with titer of anti-SARS-CoV-2 IgG 85 ± 5 Index (S/C) was described a lower concentration of VLDL and TG then in donors – 0 Index (S/C). These changes may be linked to a potential risk of cardiovascular disease (CVD). Our work can be useful for future research targeting the study of the changes in lipid metabolism during SARS-CoV-2 infection and in the development of the treatment of COVID-19 or laboratory diagnostics of physiological processes in the post-COVID-19 period.
References
Cappi S.B., Noritomi D.T., Velasco I.T., Curi R., Loureiro T.C., Soriano F.G. Dyslipidemia: a prospective controlled randomized trial of intensive glycemic control in sepsis. Intensive Care Med. 2012; 38:634–641.
Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004; 45:1169–1196.
Deniz O., Gumus S., Yaman H., Ciftci F., Ors F., Cakir E., Tozkoparan E., Bilgic H., Ekiz K. Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis. Clin Biochem. 2007; 40:162–166.
Deniz O., Tozkoparan E., Yaman H., Cakir E., Gumus S., Ozcan O., Bozlar U., Bilgi C., Bilgic H., Ekiz K. Serum HDL-C levels, log (TG/HDL-C) values and serum total cholesterol/HDL-C ratios significantly correlate with radiological extent of disease in patients with community-acquired pneumonia. Clin Biochem. 2006; 39:287–292.
Fan J., Wang H., Ye G., Cao X., Xu X., Tan W., Zhang Y. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020; 107:154243. doi: 10.1016/j.metabol.2020.154243.
Wei X., Zeng W., Su J., Wan H., Yu X., Cao X., Tan W., Wang H. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020; 14(3):297-304. doi: 10.1016/j.jacl.2020.04.008.
Nie, S., Zhao, X., Zhao, K., Zhang, Z., Zhentao, Z., Zhang, Z., et al. (2020). Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study. MedRxiv [Preprint]. doi: 10.1101/2020.03.24.20042283.
Zhao T., Wang C., Duan B., Yang P., Wu J., Zhang Q. Altered Lipid Profile in COVID-19 Patients and Metabolic Reprogramming. Front Microbiol. 2022; 13. doi: 10.3389/fmicb.2022.863802.
Changaripour S., Sarvazad H., Barghi M., Sajadi E., Sadeghian M.H., Roozbahani N.E. Lipid profile changes in patients with COVID-19 referred to medical centers in Kermanshah, Iran; a case-control study. J Int Med Res. 2022; 50(2). doi: 10.1177/03000605221078699.
Orsi E. Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. Cardiovasc. Diabetol. 2021; 20(1): 28.
Malik J., Laique T., Ishaq U., et al. Effect of COVID-19 on Lipid Profile and its Correlation with Acute Phase Reactants. medRxiv; 2021. DOI: 10.1101/2021.04.13.21255142.
Zbirnyk metodychnykh rekomendatsii z vykorystannia test naboriv firmy vyrobnyka "Human" [Electronic resourse] – Access mode: http://www.human.de/en/productNew/Clinical_Chemistry/Reagents_and_Consumables/Multipurpose_Reagents.php.
Surma S., Banach M., Lewek J. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. Lipids Health Dis. 2021; 20(1):141. doi: 10.1186/s12944-021-01563-0.
Liu Y., Pan Y., Yin Y. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J. 2021; 18(157). https://doi.org/10.1186/s12985-021-01604-1.
Peng Z., Zhenzhou W., Zhe D. Serum triglyceride levels and related factors as prognostic indicators in COVID-19 patients: A retrospective study. ImmunInflamm Dis 2021; 9(3): 1055-1060.
Zhao M., Luo Z., He H., Shen B., Liang J., Zhang J., Ye J., Xu Y., Wang Z., Ye D., Wang M., Wan J. Decreased Low-Density Lipoprotein Cholesterol Level Indicates Poor Prognosis of Severe and Critical COVID-19 Patients: A Retrospective, Single-Center Study. Front Med (Lausanne). 2021;8. doi: 10.3389/fmed.2021.585851.
Yan B., Chu H., Yang D., Sze K.H., Lai P.M., Yuan S. Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication. Viruses. (2019) 11:73. doi: 10.3390/v11010073 .
Prenner S.B., Mulvey C.K., Ferguson J.F., Rickels M.R., Bhatt A.B., Reilly M.P. Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis. 2014; 236(2):244-50. doi: 10.1016/j.atherosclerosis.2014.07.008.
Cho, K.-H., Kim, J.-R., Lee, I.-C., and Kwon, H.-J. Native High-Density Lipoproteins (HDL) With Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity. Antioxidants. 2021; 10: 209. doi:10.3390/antiox10020209.
Wang G., Deng J., Li J., Wu C., Dong H., Wu S., Zhong Y. The Role of High-Density Lipoprotein in COVID-19. Front Pharmacol. 2021; 12. doi: 10.3389/fphar.2021.720283.
